Abstract
α-synuclein is a recently discovered protein that was first identified as the major non amyloid component of senile plaques, the cerebral lesion likely responsible for Alzheimers disease. The role of α-synuclein in another brain disease namely Parkinsons disease, has been more deeply documented. It appears that α-synuclein fills up the intracytoplasmic inclusions called Lewy bodies that likely contribute to the etiology of Parkinsons disease. Furthermore, rare familial forms of Parkinsons disease have been shown to be linked to autosomal dominant mutations of α-synucleins. Is α-synuclein a bridge between Alzheimers and Parkinsons diseases? Could it be seen as a common denominator for these two neurodegenerative diseases? These issues could be better addressed by further delineating the physiological function of α-synuclein and, as a corollary, the dysfunction taking place along with the diseases. Here, I will review the recent advances concerning the physiology of α-synuclein and will particularly focus on the post-traductional events leading to drastic biophysical transformations. I will describe recent works suggesting that these modifications directly modulate the normal function of α-synuclein, likely accounting for the dysfunction associated with Parkinsons disease and perhaps contributing to Alzheimers pathology.
Keywords: synuclein cell biology, synuclein, parkinson disease, lewy bodies
Current Molecular Medicine
Title: Recent Advances on α-Synuclein Cell Biology: Functions and Dysfunctions
Volume: 3 Issue: 1
Author(s): C. Alves da Costa
Affiliation:
- IPMC du CNRS, UMR6097, 660 Route des Lucioles, Sophia Antipolis, 06560, Valbonne,France,France
Keywords: synuclein cell biology, synuclein, parkinson disease, lewy bodies
Abstract: α-synuclein is a recently discovered protein that was first identified as the major non amyloid component of senile plaques, the cerebral lesion likely responsible for Alzheimers disease. The role of α-synuclein in another brain disease namely Parkinsons disease, has been more deeply documented. It appears that α-synuclein fills up the intracytoplasmic inclusions called Lewy bodies that likely contribute to the etiology of Parkinsons disease. Furthermore, rare familial forms of Parkinsons disease have been shown to be linked to autosomal dominant mutations of α-synucleins. Is α-synuclein a bridge between Alzheimers and Parkinsons diseases? Could it be seen as a common denominator for these two neurodegenerative diseases? These issues could be better addressed by further delineating the physiological function of α-synuclein and, as a corollary, the dysfunction taking place along with the diseases. Here, I will review the recent advances concerning the physiology of α-synuclein and will particularly focus on the post-traductional events leading to drastic biophysical transformations. I will describe recent works suggesting that these modifications directly modulate the normal function of α-synuclein, likely accounting for the dysfunction associated with Parkinsons disease and perhaps contributing to Alzheimers pathology.
Export Options
About this article
Cite this article as:
da Costa Alves C., Recent Advances on α-Synuclein Cell Biology: Functions and Dysfunctions, Current Molecular Medicine 2003; 3(1) . https://dx.doi.org/10.2174/1566524033361690
| DOI https://dx.doi.org/10.2174/1566524033361690 |
Print ISSN 1566-5240 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Functional Roles of Benzothiazole Motif in Antiepileptic Drug Research
Mini-Reviews in Medicinal Chemistry Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism A Spectrum of Topics for 2019: Advances in Neuroinflammation, Oxidative Stress, Obesity, Diabetes Mellitus, Cardiovascular Disease, Autism, Exosomes, and Central Nervous System Diseases
Current Pharmaceutical Design Monocarboxylate Transporter 1 in Brain Diseases and Cancers
Current Drug Metabolism Differential Scanning Calorimetry as a Tool to Investigate the Transfer of Anticancer Drugs to Biomembrane Model
Current Drug Targets Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Cyclooxygenase-2 in Synaptic Signaling
Current Pharmaceutical Design Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Modeling Neuronal Diseases in Zebrafish in the Era of CRISPR
Current Neuropharmacology Antioxidant SkQ1 Alleviates Signs of Alzheimer’s Disease-like Pathology in Old OXYS Rats by Reversing Mitochondrial Deterioration
Current Alzheimer Research Integration of <sup>18</sup>FDG-PET Metabolic and Functional Connectomes in the Early Diagnosis and Prognosis of the Alzheimer's Disease
Current Alzheimer Research Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Effects of Psychological Stress on Depression
Current Neuropharmacology Integrated Biomarkers for Depression in Alzheimer’s Disease: A Critical Review
Current Alzheimer Research The Neuropathology of Vascular Disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)
Current Alzheimer Research Molecular Imaging of σ<sub>1</sub> Receptors In Vivo: Current Status and Perspectives
Current Medicinal Chemistry Applications of Lentiviral Vectors for shRNA Delivery and Transgenesis
Current Gene Therapy Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design

